Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity
Authors:
- Andrew A. DavisADAndrew A. Davis
- Ellen JaegerEJEllen Jaeger
- Ian S. HagemannIHIan S. Hagemann
- Amir BehdadABAmir Behdad
- Kayla Viets LayngKLKayla Viets Layng
- Lorenzo GerratanaLGLorenzo Gerratana
- Elizabeth MauerEMElizabeth Mauer
- Ami N. ShahASAmi N. Shah
- Paolo D’aMicoPDPaolo D’aMico
- Lisa FlaumLFLisa Flaum
- Carolina ReduzziCRCarolina Reduzzi
- Katie NavoKNKatie Navo
- 14 August 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (21) , 4485-4494
Abstract
Purpose: Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, but distinct treatment strategies are limited. Better characterization of the genomic and transcriptomic landscape is critical to elucidate ILC tumor biology, improve histologic classification, and define precision medicine treatment approaches. Experimental Design: We retrospectively analyzed de-identified next-generation sequencing data of 4,613 metastatic patients from the Tempus database including 637 with ILC, 91 with mixed lobular/ductal histology, and 3,885 with invasive breast carcinoma of no special type (IBC-NST). Samples were profiled using the Tempus xT assays. Results: Mutations in CDH1 occurred in 71% of patients with ILC (453/637). The median tumor mutational burden was significantly higher in CDH1-mutant ILC samples compared with wild-type (WT) CDH1 samples (P = 0.008). Mutations in PIK3CA (55% vs. 28%), ERBB2 (13% vs. 4.3%), and TBX3 (12% vs. 3.8%) were enriched in CDH1-mutant ILC versus CDH1-WT ILC. CDH1 expression was similar between CDH1-mutant ILC and CDH1-WT ILC samples (P = 0.11). Patients with CDH1-mutant mixed histology or IBC-NST had lower CDH1 expression than those with CDH1-WT mixed histology or IBC-NST (P < 0.001). ILC had a different distribution of PAM50 subtypes compared with IBC-NST and mixed histologies (P < 0.001). Conclusions: Our real-world data illustrate the distinct molecular landscape of CDH1-mutant metastatic ILC, and therapies targeting ERBB2 and PIK3CA should be further investigated in CDH1-mutant ILC. ILC differs from mixed and IBC-NST at a transcriptional level, suggesting the possibility of using CDH1 RNA expression levels to improve classification of ILC.Keywords
All Related Versions
Funding Information
- AACR-Lobular Breast Cancer Alliance-Deborah Mueller Foundation Fund Invasive Lobular Carcinoma Innovation and Discovery Grant (24-80-70-REDU)
This publication has 32 references indexed in Scilit:
- Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With ImmunotherapyJAMA Network Open, 2023
- Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerEBioMedicine, 2022
- Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancerLaboratory Investigation, 2022
- Invasive lobular carcinoma: an understudied emergent subtype of breast cancerBreast Cancer Research and Treatment, 2022
- Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort studyEuropean Journal of Cancer, 2022
- Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancerCancer, 2020
- Prevalence and mutational determinants of high tumor mutation burden in breast cancerAnnals of Oncology, 2020
- Integrated genomic profiling expands clinical options for patients with cancerNature Biotechnology, 2019
- Lobular breast cancer: Clinical, molecular and morphological characteristicsPathology - Research and Practice, 2016
- Comprehensive Molecular Portraits of Invasive Lobular Breast CancerCell, 2015